Research programme: exosome-based inflammatory bowel disease therapeutics - EXO Biologics
Latest Information Update: 28 Jun 2024
At a glance
- Originator EXO Biologics
- Class Anti-inflammatories; Exosome therapies
- Mechanism of Action Exosome replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 12 Jun 2024 EXO Biologics has patents pending for extracellular vesicles (EVs) derived from mesenchymal stromal cells and method for obtaining said EVs in Australia, Japan, Europe, Israel, Canada, South Korea, USA, China, Mexico, Brazil and worldwide
- 12 Jun 2024 EXO Biologics has patents pending for extracellular vesicles and compositions thereof in USA, Europe and worldwide
- 12 Jun 2024 EXO Biologics has patents pending for process for the manufacturing of protein-associated extracellular vesicles in Europe, Mexico, South Korea, Canada, Israel, Australia, China, USA, Japan, Brazil and worldwide